Free Trial

Whitehawk Therapeutics (WHWK) Competitors

$1.88 +0.03 (+1.62%)
As of 09:34 AM Eastern

WHWK vs. ATXS, AURA, ARCT, GLUE, RNAC, CADL, INBX, PRTA, ALT, and TNXP

Should you be buying Whitehawk Therapeutics stock or one of its competitors? The main competitors of Whitehawk Therapeutics include Astria Therapeutics (ATXS), Aura Biosciences (AURA), Arcturus Therapeutics (ARCT), Monte Rosa Therapeutics (GLUE), Cartesian Therapeutics (RNAC), Candel Therapeutics (CADL), Inhibrx Biosciences (INBX), Prothena (PRTA), Altimmune (ALT), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry.

Whitehawk Therapeutics vs. Its Competitors

Astria Therapeutics (NASDAQ:ATXS) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Astria Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

In the previous week, Astria Therapeutics' average media sentiment score of 0.93 beat Whitehawk Therapeutics' score of 0.00 indicating that Astria Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Astria Therapeutics Positive
Whitehawk Therapeutics Neutral

Astria Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 383.87%. Given Astria Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Astria Therapeutics is more favorable than Whitehawk Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Astria Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.25
Whitehawk Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

99.0% of Astria Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 4.5% of Astria Therapeutics shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Whitehawk Therapeutics has higher revenue and earnings than Astria Therapeutics. Astria Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Astria TherapeuticsN/AN/A-$94.26M-$1.87-3.32
Whitehawk Therapeutics$25.98M3.41-$63.69M$0.1611.75

Whitehawk Therapeutics has a net margin of 99.42% compared to Astria Therapeutics' net margin of 0.00%. Astria Therapeutics' return on equity of -47.18% beat Whitehawk Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Astria TherapeuticsN/A -47.18% -31.26%
Whitehawk Therapeutics 99.42%-56.73%-48.68%

Summary

Astria Therapeutics beats Whitehawk Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Whitehawk Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for WHWK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WHWK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WHWK vs. The Competition

MetricWhitehawk TherapeuticsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$88.57M$761.07M$2.18B$9.34B
Dividend YieldN/A4.84%2.60%4.06%
P/E Ratio11.751.3922.2019.86
Price / Sales3.4125.51102.9699.92
Price / CashN/A19.5613.4057.94
Price / Book0.896.7275.835.67
Net Income-$63.69M-$4.32M-$127.36M$257.80M
7 Day Performance-1.57%-0.31%1.00%1.86%
1 Month PerformanceN/A1.39%2.10%10.91%
1 Year PerformanceN/A1.51%21.42%18.51%

Whitehawk Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WHWK
Whitehawk Therapeutics
N/A$1.88
+1.6%
N/AN/A$88.57M$25.98M11.7540Gap Down
ATXS
Astria Therapeutics
1.6355 of 5 stars
$6.33
+0.3%
$30.00
+373.9%
-44.9%$357.23MN/A-3.3930
AURA
Aura Biosciences
2.5367 of 5 stars
$6.95
+5.9%
$22.00
+216.5%
-22.8%$349.38MN/A-3.6650News Coverage
Positive News
ARCT
Arcturus Therapeutics
1.9751 of 5 stars
$12.85
-2.3%
$54.00
+320.2%
-44.2%$348.49M$152.31M-5.08180
GLUE
Monte Rosa Therapeutics
2.1226 of 5 stars
$5.61
+7.3%
$15.33
+173.3%
+24.5%$345.07M$75.62M70.1390News Coverage
Positive News
RNAC
Cartesian Therapeutics
2.4835 of 5 stars
$13.27
-2.3%
$40.00
+201.4%
-32.0%$344.41M$34.17M-0.2564Positive News
CADL
Candel Therapeutics
2.5176 of 5 stars
$6.85
+9.6%
$22.00
+221.2%
+5.3%$343.19M$120K-5.1160Positive News
INBX
Inhibrx Biosciences
2.6082 of 5 stars
$23.65
+3.0%
N/A+69.8%$342.36M$200K0.20166
PRTA
Prothena
3.611 of 5 stars
$6.32
+1.6%
$31.50
+398.4%
-72.9%$340.21M$135.16M-3.04130
ALT
Altimmune
2.2188 of 5 stars
$4.18
flat
$18.20
+335.4%
-45.9%$339.03M$20K-3.3250
TNXP
Tonix Pharmaceuticals
2.5985 of 5 stars
$45.06
+1.9%
$585.00
+1,198.3%
-20.8%$331.64M$10.09M-0.0250Gap Up

Related Companies and Tools


This page (NASDAQ:WHWK) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners